Meletios A. Dimopoulos

Meletios A. Dimopoulos, MD is Professor and Chairman of the Department of Clinical Therapeutics at the National and Kapodistrian University of Athens and Head of Hematology at Alexandra General Hospital. He is among the most cited hematologists in the world and is the principal co-investigator of the POLLUX and CASTOR trials — two seminal phase III studies that established daratumumab combinations as the standard of care for relapsed/refractory multiple myeloma. The POLLUX trial (NEJM 2016) demonstrated that daratumumab plus lenalidomide/dexamethasone (D-Rd) significantly improved PFS compared with Rd alone, while CASTOR (NEJM 2016) showed similar superiority for daratumumab plus bortezomib/dexamethasone (D-VD) — together leading to the FDA approvals that transformed relapsed myeloma management. Dr. Dimopoulos is also the world's foremost expert on Waldenström macroglobulinemia (WM), having co-discovered the pathognomonic MYD88 L265P mutation and led trials of ibrutinib-based therapy in WM. He has participated in or led more than 200 clinical trials, published over 1,500 peer-reviewed manuscripts with an extraordinary h-index, and serves as past president of the European Myeloma Network and European Hematology Association.